Search Medical Journals & Research Articles

[Corrections] Correction to Lancet HIV 2024; 11: e793–94

Gökengin D. Outcomes and gaps in HIV care for migrants in Europe. Lancet HIV 2024; 11: e793–94—In the fourth sentence of the third paragraph of this Comment, the percentage for the risk of virological failure among migrants changed to 93% during corrections to the original research on which this Comment was based. This correction has been made as of Oct 6, 2025.

[Corrections] Correction to Lancet HIV 2025; 12: e473–84

Ryan P, Blanco JL, Masia M, et al. Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. Lancet HIV 2025; 12: e473–84—In this Article in the third sentence of paragraph four of the Results, mean adjusted weight change from baseline should have been 1·81 kg (95% CI 1·28–2·34) in the bictegravir group. This correction has been made as of Sept 25, 2025.

[Corrections] Correction to Lancet HIV 2025; published online June 11. https://doi.org/10.1016/S2352-3018(25)00158-4

Ratevosian J, Reid M, Ni Z, et al. Reimagining HIV prevention with artificial intelligence. Lancet HIV 2025; published online June 11. https://doi.org/10.1016/S2352-3018(25)00158-4—In this Comment, a reference to use of artificial intelligence in a Nigerian pre-exposure prophylaxis programme was incorrect, and the text and references have been updated. This correction has been made as of Sept 5, 2025.

[Corrections] Correction to Lancet HIV 2025; 12: e638–48

Walters MK, Bulterys MA, Barry M, et al. Probability of vertical HIV transmission: a systematic review and meta-regression. Lancet HIV 2025; 12: e638–48—In the “Previous reviews” section of figure 1 of this Article, the number of reviews excluded from Stover et al has been corrected to “3”. In table 1, the number of weeks on ART for Option B+ has been corrected to “5–39 weeks”. The third sentence of the penultimate paragraph of the Results has been corrected to “The percent difference was largest for monthly breastfeeding transmission probability among women with CD4 higher than 350 cells per μL (table 2).” These corrections have been made as of Aug 27, 2025.

[Corrections] Correction to Lancet HIV 2023; 10: e528–42

Stannah J, Soni N, Lam JKS, et al. Trends in HIV testing, the treatment cascade, and HIV incidence among men who have sex with men in Africa: a systematic review and meta-analysis. Lancet HIV 2023; 10: e528–42—In figure 7 of this Article, the scale for incidence per 100 person-years in part C was incorrect. The correction has been made as of July 30, 2025.

[Corrections] Correction to Lancet HIV 2025; 12: e473–84

Ryan P, Blanco JL, Masia M, et al. Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. Lancet HIV 2025; 12: e473–84—In table 1 of this Article, data for “Previous AIDS (CDC criteria): No” in the dolutegravir and lamivudine group should have been 215 (78%). This has been corrected as of July 1, 2025.

[Corrections] Correction to Lancet HIV 2025; 12: e130–42

Hendrickson C, Hirasen K, Mongwenyana C, et al. Costs and outcomes of routine HIV oral pre-exposure prophylaxis implementation across different service delivery models and key populations in South Africa: a retrospective cohort study. Lancet HIV 2025; 12: e130–42—In this Article, the second sentence of the fourth paragraph of the Results section should read “The proportion of PrEP clients returning for at least one follow-up visit varied greatly, from only 1·9% at one MSM-focused outreach programme to 83·7% at another clinic focused on MSM”; in addition, in table 4, the number of clients attending at least one follow-up visit for the outreach programme at MSM site 2 should be 1 (1·9%).

[Corrections] Correction to Lancet HIV 2025; published online March 26. https://doi.org/10.1016/S2352-3018(25)00074-8

ten Brink D, Martin-Hughes R, Bowring AL et al. Impact of an international HIV funding crisis on HIV infections and mortality in low-income and middle-income countries: a modelling study. Lancet HIV 2025; published online March 26. https://doi.org/10.1016/S2352-3018(25)00074-8—In this Article, in the ninth paragraph of the Results section, the deaths for scenario 5 should have been 106 300 and the percentage of additional child deaths should have been 109·7%. Formatting errors in the appendix have also been updated.

[Corrections] Correction to Lancet HIV 2024; 11: e31–41

Shing JZ, Engels EA, Austin AA, et al. Survival by sex and HIV status in patients with anal cancer in the USA between 2001 and 2019: a retrospective cohort study. Lancet HIV 2024; 11: e31–41—The first sentence of the Introduction should have read “Human papillomavirus (HPV) causes 90% of anal squamous cell carcinomas (SCCs) worldwide, most of which are diagnosed in high-resource settings”. This correction has been made as of March 16, 2025.

[Correspondence] Alternatives to the three-test strategy for HIV diagnosis

WHO recommends a three-test strategy for HIV diagnosis, requiring at least three consecutive reactive rapid diagnostic tests (RDTs) from different companies to confirm a positive result.1 This strategy aims to ensure diagnostic accuracy and avoid lifelong consequences of false positive diagnoses. Some facilities using the three-test strategy in Malawi had decreased rates of misdiagnosis, with minimal effects on the overall cost of HIV testing services.1

[Comment] Should we be paying more attention to HIV and adult ADHD?

People living with HIV bear a substantially increased burden of mental health challenges compared with people without HIV. Beyond its impact on quality of life, diminished mental health is associated with reduced access and adherence to antiretroviral therapy (ART), higher viral load, and, consequently, potentially increased likelihood of onward transmission and advanced HIV disease.1 Better understanding and management of psychiatric conditions among people living with HIV is therefore key in meeting UNAIDS goals of reducing HIV transmission and advanced HIV disease-related mortality by 2030.

[Comment] The HIV care crisis in the Philippines

HIV cases continue to rise at an alarming rate in the Philippines, with a current incidence 543% that of 2010 estimates, reflecting deep-seated policy gaps and an inadequate national response.1 In response to this increase in HIV incidence, the Department of Health has now recommended that the national government declare the HIV epidemic as a national emergency.

[Editorial] The clock is ticking for UNAIDS

In March, 2025, UN Secretary-General António Guterres launched UN80, an initiative marking the 80th anniversary of the founding of the organisation. Acknowledging changing global priorities and shocks to aid financing, the UN80 initiative is intended to adapt the UN for the present day by improving efficiency and ensuring processes are fit for purpose. The UN80 proposal “to sunset UNAIDS by the end of 2026”, which “would entail mainstreaming capacity and expertise into relevant entities of the UN development system in 2027”, was both surprising and, to some, seemingly inevitable.

[Personal View] Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials

Identifying safe and effective therapies that target the underlying cause of cystic fibrosis remains a key priority for the cystic fibrosis community. CFTR modulators are first-in-class, regulatory-approved therapies that improve the function of the protein encoded by the CFTR gene and are associated with dramatic and sustained clinical benefits. Although approximately 90% of the population with cystic fibrosis could benefit from these therapies based on genetic eligibility, a crucial unmet need remains: developing CFTR-directed therapies for the ultra-rare population with cystic fibrosis who are not candidates for CFTR modulators due to either ineligibility or intolerance.

[Articles] Projecting the 30-year burden of obstructive sleep apnoea in the USA: a prospective modelling study

Projections indicate that obstructive sleep apnoea will affect 76·6 million adults aged 30–69 years across the USA in 2050, with a disproportionate growth among females compared with males. These findings highlight the urgent need for targeted public health strategies and revised access to diagnosis and follow-up pathways to address the growing prevalence of obstructive sleep apnoea, particularly among females.